

The Journal of Phytopharmacology

(Pharmacognosy and phytomedicine Research)

Review Article

ISSN 2320-480X

JPHYTO 2022; 11(6): 414-420

November- December

Received: 03-10-2022

Accepted: 19-11-2022

Published: 20-12-2022

©2022, All rights reserved

doi: 10.31254/phyto.2022.11607

Acharya Balkrishna

1. University of Patanjali, Patanjali
Yogpeeth, Haridwar-249405,
Uttarakhand, India.

2. Patanjali Herbal Research
Department, Patanjali Research Institute,
Haridwar-249405, Uttarakhand, India

Vidhi Dobhal

Patanjali Herbal Research Department,
Patanjali Research Institute, Haridwar-
249405, Uttarakhand, India

Sonam Verma

Patanjali Herbal Research Department,
Patanjali Research Institute, Haridwar-
249405, Uttarakhand, India

Deepika Srivastava

Patanjali Herbal Research Department,
Patanjali Research Institute, Haridwar-
249405, Uttarakhand, India

Shalini Singh

Patanjali Herbal Research Department,
Patanjali Research Institute, Haridwar-
249405, Uttarakhand, India

Vedpriya Arya

1. University of Patanjali, Patanjali
Yogpeeth, Haridwar-249405,
Uttarakhand, India.

2. Patanjali Herbal Research
Department, Patanjali Research Institute,
Haridwar-249405, Uttarakhand, India

Correspondence:

Vidhi Dobhal

Patanjali Herbal Research Department,
Patanjali Research Institute, Haridwar-
249405, Uttarakhand, India

Email: vidhi.dobhal@patanjali.res.in,
phrd.publications@patanjali.res.in

Arctigenin: A Potential Component with Multifaceted Therapeutic Properties

Acharya Balkrishna, Vidhi Dobhal, Sonam Verma, Deepika Srivastava, Shalini Singh, Vedpriya Arya

ABSTRACT

Medicinal plants are an excellent source of new therapeutic drugs because of their phytochemical constituents. *Arctium lappa* L. (common name-burdock) is a perennial medicinal herb commonly found in China, Japan, Korea traditionally used as promising health supplement. Major active constituent of *A. lappa* L. seeds are arctigenin which exhibits pharmacological potential such as anti-inflammatory, anticancer, antimicrobial and hepatoprotective properties. The purpose of this study is to provide an up-to-date evaluation of the literature on the pharmacological activities of Arctigenin from *Arctium lappa* L. Literature is collected from Google scholar, Science Direct, Research Gate, PubMed, Google, and SciFinder databases published between 2012 and 2021 (Jan). Keywords used to retrieve the data are pharmacological profile, arctigenin, and *Arctium lappa* L. The antioxidant, anti-inflammatory, anti-tumor, hepatoprotective, renoprotective, neuroprotective, and CNS depressant properties of arctigenin demonstrated its pharmacological significance among traditional science. According to different research, arctigenin is effective in the treatment of a variety of chronic disorders, including cancer (stomach, lungs, liver, and colon) and inflammatory diseases (rashes, and other skin conditions.). Future experiments based on the mechanism pathway responsible for the protective role of arctigenin's will help the scientist to uncover its health benefits.

Keywords: *Arctium lappa*, Arctigenin, Botanical description, Medicinal uses, Pharmacological profile.

INTRODUCTION

Herbal medicine, encompasses ancient medical systems such as Ayurveda, Chinese herbal medicine, and Kampo^[1], which uses different plant parts and their extracts or fractions for therapeutic benefits^[2]. Herbal medicine is well-known for its potential role as a complementary treatment for a variety of ailments. Traditional methods have also grown in popularity and recognition in recent years in terms of socioeconomic standing. These extracts have a range of action mechanisms^[1]. Stir-heating, charring, steaming, boiling, and calcining are examples of traditional Chinese medicine treatments, dispensing, and preparations that have been used to improve the effectiveness and/or minimise the toxicity of crude medicines. It is commonly used to get rid of 'wind-heat,' ease sore throat inflammation and swelling, and detoxify the body^[3].

With 1600 genera and over 23000 species worldwide, the Asteraceae family is one of the largest flowering plant families^[4]. The genus *Arctium* L., popularly known as "burdock," is a group of biennial herbs that can be found along roadsides, streams, and waste sites, as well as in forests in temperate Europe and Asia and in subtropical and tropical locations. *Arctium* species contain nonvolatile compounds such as acetylenic compounds, lignans, phytosterols, fatty acids, polysaccharides, flavonoids, caffeoylquinic acid derivatives, terpenes/terpenoids, and volatile compounds such as carboxylic and fatty acids, hydrocarbons, aldehydes, methoxypyrazines, sesquiterpenes and monoterpenes. The *Arctium* genus possessed pharmacological properties including gastroprotective, hepatoprotective, anti-allergic, anti-cancer, anti-diabetic, antimicrobial, anti-oxidant, antiviral, and anti-inflammatory effects^[5].

Plant morphology- *Arctium lappa* (burdock) L., also known as "niupang" in Chinese and "gobo" in Japanese^[6]. It is a European and Asian native that is increasingly spreading through North America^[7]. Burdock is an herbaceous biennial plant with pubescent to subglabrous epigeal portions that grows up to 150 cm tall. The basal leaves are oval, cordate, and hollow petioles with a diameter of 50 cm. The stems are branching and have corymbose capitula at the end. Florets are the same length as the involucre bracts. The roots are slender (about 0.71 m long and 0.20.3 m across), very crisp, and have a sweet, mild, and pungent flavour^[5].

Ethnomedicinally, *A. lappa* L. (a.k.a. Burdock) root is eaten in many parts of Asia and is used in folk medicine to treat infectious diseases^[7]. In several parts of Asia, the root is eaten and used to treat infectious diseases, while the seeds are used as an herbal medicine to treat inflammatory disorders^{[9][10]}. Eastern Asian countries produce and eat plants as food (particularly China, Japan, and Korea). The plant is also abundantly medicinal and edible in China's Shandong and Jiangsu provinces^[9]. Burdock contains polyphenols, burdock aldehydes, and other nutrients in addition to protein, oligosaccharides, and other nutrients. Burdock extracts demonstrated biological effects like anti-cancer, anti-inflammatory, antiparasitic, antimicrobial, anti-diabetic and hepatoprotective activities^{[11][12][13]}. Sore throats, boils, rashes, and other skin disorders have all been treated with this plant in the past. Burdocks commonly used in traditional Chinese medicine to treat burns, tumors, eczema, gout, and hepatitis. The plant is generally referred to as 'bardana' in Brazil, and it has been used as a digestive stimulant, depurative, diuretic and in dermatological conditions^{[13][8]}. In traditional medicine, seeds are employed as a diuretic, antipyretic, or detoxifying agent^[14].

A. lappa root is high in phenols, saponins, lignans, tannin, and flavonoids, according to phytochemical studies. ^[15]. The primary active compounds identified from this plant include arctigenin (ARG), tanin, arctiin, chlorogenic acid, caffeic acid, beta-eudesmol, trachelogenin, inulin, sitosterol-beta-D-glucopyranoside, diartigenin and lappaol. Among them, two important lignans present in the roots, ARG and arctiin, are known to have anti-inflammatory, anti-allergic, anticancer, and anti-metastatic activities. Burdock leaves, fruit/seeds, and burdock roots are also used for various medicinal purposes^[11].

Most of the pharmacological activity of ARG (the key component of *A. lappa*) has been studied in recent years ^[17]. Arctigenin is a compound extracted from seeds of *Arctium lappa* L. (Asteraceae), a Chinese, Japanese, and Korean medicinal herb. Arctigenin has been proven to have anti-oxidant, anti-inflammatory, and anti-tumor characteristics. ARG is thought to have anti-tumor properties by preventing Nuclear factor- κ B (NF- κ B) from translocating to the nucleus. ARG promotes apoptosis and anti-metastatic effects in breast cancer cell^[11]. The current review article aims to include an up-to-date literature review on ARG's detailed pharmacological activities, with an emphasis on its significance.




Figure 1: *Arctium lappa* L. and its active constituent, Arctigenin

METHODOLOGY

This review paper was prepared by integrating and analysing prior research on 'Arctigenin' compound from *Arctium lappa* L., its medicinal uses and scientific validity. Several data sources, including Google Scholar, Science Direct, Research Gate, PubMed, Chem draw, and other Google search engines, were used to examine a total of 67 published articles in between 2012 to 2021. Using a collection of keywords, including '*A. lappa* L.', 'Arctigenin', 'Botanical description', 'Medicinal uses', 'Pharmacological profile,' etc., only published works in English were selected as search targets across many databases. Although we acknowledge that there may be

some additional data in less accessible forms, such as unpublished research, the literature search in this paper was restricted to scientific publications included in the aforementioned databases that may be available to the scientific community as references.

ARCTIGENIN AND ITS SCIENTIFIC EVIDENCES

'Arctigenin', the main constituent obtained from seeds of *Arctium lappa* L. that have been used as an herbal medicine or functional food to treat various diseases such as inflammation, cancer, diabetes as well as showed protective effect on different organ *i.e.*, liver, kidney, heart. We have reviewed the pharmacological profile of this compounds that has been described in Table 1.

Anti-inflammatory activity

Arctigenin exerted significant anti-inflammatory effect on LPS stimulated RAW264.7 macrophages cells (*in-vitro*) and thioglycolate induced acute peritonitis in C57BL/6 mice (*in-vivo*) by inhibiting phosphorylation of p65 and p38 and suppressing neutrophils, macrophages, and chemokines, pro-inflammatory cytokines as compared to the normal control group^[11]. In another study, ARG administration at 50 mg/kg was found to be anti-inflammatory against lipopolysaccharide (LPS)- induced endotoxin shock in the bone marrow-derived MDSCs (*in-vitro*) and lipopolysaccharide (LPS)-induced acute inflammation in C57BL/6 mice (*in vivo*) when compared with LPS group^[15]. Similarly, ARG administration (50 mg/kg) displayed anti-inflammatory activity on lipopolysaccharide (LPS)-induced acute lung injury in male C57BL/6 wild-type mice, by inhibiting different inflammatory parameters such as MDA, iNos, NO, phosphorylation of mitogen-activated protein kinases (MAPKs and SOD, CAT, GSH/GSSG) when compared with LPS treated group^[16]. ARG (10 μ M) showed significant anti-inflammatory potential against LPS-stimulated peritoneal macrophages through inhibition of IL-1 β , IL-6, TNF- α expression, PI3K, AKT and IKK β phosphorylation while stimulating IL-10 and CD204 expression. In animal study, ARG at 5 mg/kg suppressed blood IL-1b, TNF-a level, PI3K, AKT and IKKb phosphorylation as well as NF- κ B activation while increased IL-10 and CD 204 expression in 2,4,6-trinitrobenzene sulfonic acid (TNBS)- induced colitis in the mice when compared with diseased group^[17].

Anti-cancer activity

Arctigenin from *A. lappa* showed significant inhibition on proliferation of glioma cells (U87MG and T98G) by inducing autophagy and apoptosis through the AKT/mTOR pathway (concentration at 400 μ M) as compared to the control group^[13]. ARG significantly inhibited proliferation, invasion, and the stemness of cancer cells via decreasing the tumor-promoting cytokines GM-CSF, MMP-3, MMP-9, and TSLP both in murine mammary cancer cell line and in human breast cancer cell tumor-bearing BALB/c female mice^[18]. When compared to doxorubicin, ARG at 10-200 M boosted the cytotoxic effect of doxorubicin-induced cell death by causing extended p21 expression and p38-mediated AIF-dependent cell death in MDA-MB-231 human breast cancer cells^[19]. Additionally, ARG showed anti-metastasis and anti-epithelial-mesenchymal transition in hepatocellular carcinoma through inhibiting migration and invasion of cells with epithelial up-regulation while, down-regulating the mesenchymal marker proteins. It also activated the Wnt/-catenin signalling pathway, resulting in the down-regulation of -catenin target genes such as c-Myc, cyclin D1, MMP-9, and ZO-1. In an *in-vivo* study, it significantly reduced tumour metastasis in mice liver while inhibiting the growth of subcutaneously transplanted tumors^[20]. In addition, ARG exerts anticancer effects by proliferation and induced apoptosis in TNBC cells^[21]. By inhibiting MMP-9 and urokinase plasminogen activator (Upa) through the Akt, NF-B, and MAPK signaling pathways, ARG effectively inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced cell migration and invasion in oestrogen receptor-positive MCF-7 cells^[22]. In another study, ARG in two-drug combinations with doxorubicin showed

synergistic effects in inhibiting CaCo2 cells and CEM/ADR 5000 multidrug-resistant cells^[23]. Likewise, ARG (10 μ M) exhibited significant ($p < 0.05$) anticancer activity by inhibiting human ovarian cancer cell (OVCAR3 and SKOV3 cells) proliferation as well as STAT3 phosphorylation and expressions levels of survivin protein and iNOS compared to the control cells^[24]. Furthermore, ARG (0.10-20 μ M) inhibited proliferation in KSHV-infected PEL cells under glucose deprivation by lowering cellular ATP, mitochondrial membrane potential, and triggering caspase-9-mediated apoptosis. ARG suppress extracellular signal-regulated kinase (ERK) activity and p38 mitogen-activated protein kinase (p38 MAPK) signaling pathways by inhibiting their phosphorylation^[25].

Hepatoprotective activity

The ARG was found to be hepatoprotective in NCTC-1469 cells, the cell viability is increased similarly, ARG and SD-Na (100mg/kg) treatment reduced the generation of inflammatory mediators and the TLR4/MyD88/NF-B signalling pathway in C57BL/6 mice with toxoplasma gondii-induced liver injury (*in vivo*)^[26]. Likewise, ARG showed significant protective activity against concanavalin A (ConA) induced liver injury via suppression of immune cells, congestion, necroinflammation of livers and improved hepatic function in male BALB/c mice at 10 μ g/g administrated dose^[27]. In WRL68 hepatocytes, ARG at 50 μ M concentration inhibited OA-induced lipid aggregation, lipid peroxidation, and inflammation. It also reduced the expression of U937 lymphocyte chemoattractant, ICAM-1, IL-1, IL-6, IL-6sR, IL-7, IL-8, and sterol regulatory element-binding protein-1, thus significantly increasing the expression of carnitine palmitoyltransferase 1 and peroxisome proliferator-activated receptor alpha. ARG controls cell survival, lipid metabolism, oxidative stress, and inflammation by activating phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), AMP-activated protein kinase AMPK pathways, and phosphorylation levels of Akt and AMPK^[28].

Nephroprotective activity

Arctigenin shows nephroprotective behavior and found to increase PP2A activation and reduced p65 NF-B mediated inflammatory response and high glucose-induced migration in the cultured podocytes through interaction with Drebrin-1^[29]. It also had cytoprotective effects on high glucose-induced cell apoptosis and inhibited ER stress in db/db animals with diabetes-related renal damage^[30]. Furthermore, when compared to the I/R population, pretreatment with ARG at a high dose exacerbated I/R-induced acute kidney injury by increasing tubular cell apoptosis while reducing infiltrating inflammatory cells and proinflammatory cytokine^[31]. It was also discovered, it protected the kidney from injury by minimizing tubular dilatation, epithelial atrophy, collagen deposition, and tubulointerstitial compartment expansion, as well as inhibiting various pro-inflammatory cytokines^[32].

Neuroprotective activity

Arctigenin showed anti-depression and anti-anxiety-like properties in male ICR mice at 10 and 30 mg/kg which might possible to have

protective action towards central nervous system^[33]. ARG attenuated microglial activation and neuro-inflammation by suppressing the TLR4/NF- κ B and TNFR1/NF- κ B signaling pathways in *Toxoplasma gondii* infection induced depression in animal studies^[34]. Arctigenin reduced infarct volume, neurological score, and brain water content and attenuated ischemic stroke induced neuroinflammation and NLRP3 inflammasome activation via the SIRT1 pathway^[35]. Studies revealed that, ARG protected PC12 cells of *Rattus norvegicus* adrenal tumours from ethanol-induced injury by promoting cell proliferation, increasing the cell distribution ratio at the G2/M and S phases, and thus significantly reducing apoptosis and necrosis in ethanol-treated cells^[36]. In another study, ARG potentially reversed scopolamine-induced memory deficits in mice in a passive avoidance test by 62 % and 73 %, respectively^[37]. Moreover, arctigenin had a substantial protective effect on cerebral ischemia-reperfusion rats by inhibiting neuroinflammation^[38].

Other activities

Arctigenin possess several other therapeutic properties such as antihypertensive, vasorelaxant, cytoprotective, gastroprotective, antioxidant, osteoprotective, antifibrosis, and anti-alzheimer activities^[39-42]. Researchers have shown that spontaneously hypertensive rats (SHR), arctigenin when administered with 50 mg/kg and prevented hypertension while increasing eNOS and decreasing NADPH oxidase protein production, ROS production^[39]. Similarly, ARG protects by inhibiting Ca^{2+} influx partly through L-type calcium channel as well as enhancing Ca^{2+} efflux, Arctigenin show relaxant effect in guinea pigs^[40]. Furthermore, when ARG was tested against ethanol and acetic acid-induced ulcers in the experimental animals. it was found to prevent these gastric lesions. In addition, ARG decreased MDA and increased superoxide dismutase levels in serum, while TNF- α , interleukin-6 (IL-6 & IL-10) and C-reactive protein expression levels were significantly lower in the ARG group relative to the vehicle group^[42]. Using nitrite scavenging activity and acetylcholinesterase activity, ARG showed antioxidant and enzyme inhibitory activity^[43]. ARG blocked acetylcholinesterase and also showed antioxidant activity^[51]. Similarly, Arctigenin inhibit RANKL-induced osteoclastogenesis and hydroxyapatite resorption, as well as prevent titanium particle-induced bone degradation^[44].




Figure 2: Spectrum of Arctigenin's pharmacological activities

Table 1: Some Scientific Evidences of Arctigenin

Biological Profile	Experimental models	Mechanism	References
Anti-inflammatory	LPS stimulated RAW264.7 cells TG-induce acute peritonitis in C57BL/6 mice	ATG inhibits the phosphorylation of p65 and p38 in LPS-stimulated RAW264.7 cells ATG inhibited tissue inflammatory cell infiltration, expression of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF- α), CD11b+ Ly6G+ neutrophils percentage and F4/80+ macrophages in the spleen, chemokines CCL3 & CCL4 expression and the adhesion molecule CD62L on the surface of CD11b-positive monocytes.	[11]
	LPS-induced endotoxin shock in bone marrow cells	ARG ameliorate LPS-induced inflammation through accumulating MDSCs, especially granulocytic and enhancing the immunosuppressive function of MDSCs.	[15]
	LPS-induced acute inflammation in C57BL/6 mice.	ARG stimulates accumulation of MDSCs through upregulating miR-127-5p which targets the 3'UTR of interferon regulatory factor-8 (IRF8), M1 macrophage polarization by elevating the expression of arginase 1 (Arg-1) and inducible nitric oxide synthase (iNOS) in spleen of LPS-induced mice.	

	LPS-induced acute lung injury in C57BL/6 mice.	Inhibited MDA, iNos, NO, phosphorylation of mitogen-activated protein kinases (MAPKs and stimulated SOD, CAT, GSH/GSSG in the lung, expression of heme oxygenase-1.	[16]
	LPS-stimulated peritoneal macrophages 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice.	Inhibited IL-1b, IL-6 and TNF- α expression, PI3K, AKT and IKK β phosphorylation, p-PI3K antibody binding and the nucleus translocation of NF- κ B p65 with increase in IL-10 and CD204 expression in LPS-stimulated peritoneal macrophages. Inhibited IL-1b and TNF- α level, colon shortening, macroscopic scores, myeloperoxidase activity, TNBS-induced IL-1b, TNF- α and IL-6 expression, as well as PI3K, AKT and IKK β phosphorylation and NF- κ B activation with increase in IL-10 and CD204 expression in colitic mice	[17]
Anti-cancer	Glioma cells (U87MG and T98G)	Inhibited proliferation, invasion and migration and arrested the cell cycle through inducing apoptosis in glioma cells	[13]
	Human breast cancer in murine mammary cancer cell line (4T1) 4T1-tumor bearing BALB/c female mice.	ARG inhibited the proliferation, invasion and stemness of breast cancer cells via decreasing GM-CSF and TSLP via reducing nuclear translocation of NF- κ B p65. ARG prolonged the survival as well as hindered tumor growth, size and weight of 4T1 tumor-bearing mice. Immunohistochemistry displayed ARG markedly reduced the expression of Ki-67 in tumor tissues.	[15]
	Human breast cancer cells (MDA-MB-231).	Inhibited cell viability, MRP1 gene expression, phosphorylation, activator of transcription 3 (STAT3) expressions of RAD51 and survivin, Bcl-2 and Bcl-xl, phosphorylations and expressions of Akt and JNK, enhanced Uptake of doxorubicin, DNA damage, mitochondrial BAX levels, nuclear AIF levels, p21(cyclin-dependent kinase), p38MAPK.	[45]
	Hep G2 and SMMC 7721 cells Hepatocellular carcinoma in Athymic nu/nu mice	Inhibited the cell viability, migration, invasion of Hep G2 and SMMC 7721 cells, β -catenin target genes including c-Myc, cyclin D1, MMP-9, and ZO-1, epithelial-mesenchymal transition. Enhanced activation of Wnt/ β -catenin through a GSK3 β -dependent pathway. ARG in tumorous mice inhibits growth transplanted tumor and tumor metastasis in liver.	[18]
	Retinoblastoma cell line (Y79)	Inhibited cell viability, BCL-2, cell migration and enhanced apoptosis, BCL-2-associated X protein, JAG1	[19]
	HepG2 and Hep3B cell lines Tumor (Hep G2) bearing female BALB/c nude mice.	ARG inhibited cancer cell with IC ₅₀ 4.74nM against HepG2 cells and IC ₅₀ 59.27 nM against Hep3 B cells. Inhibited migration, invasion, colony formation by HepG2 cells gankyrin mRNA and protein, luciferase activity, PPAR α binding to C/EBP α and HCC growth in mice.	[20]
	Androgen-sensitive human prostate (LNCaP and LAPC-4) cancer cells and pre-malignant (WPE1-NA22) cells Xenograft mouse model	ARG Inhibited proliferation of LNCaP and LAPC-4 cells by 30-50%, WPE1-NA22 cells by 75% at <2 μ M ARG inhibited tumor growth, proliferation marker Ki67, total and nuclear androgen receptor and growth factors including VEGF, EGF, and FGF- β , enhanced Bax/ Bcl-2 ratio in mouse model	[16]
	Triple-negative breast cancers (TNBCs)	inhibited proliferation and induced apoptosis in TNBC cells	[22]
	Estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 human breast cancer cell lines	ARG inhibited cell migration, invasion, (MMP)-9, Akt, NF- κ B and MAPK (ERK 1/2 and JNK 1/2), heparanase proteins in both cell lines	[23]
	MDA-MB-231 cells	ARG inhibited cancer cells with IC ₅₀ 696.90 μ M.	[46]
	Multidrug-resistant CEM/ADR 5000 and CaCo2 cells	Inhibited the cell proliferation, STAT3 phosphorylation and survivin, iNOS expression, increase apoptosis, caspase-3-dependent apoptosis	[24]
	Ovarian OVCAR3 and SKOV3 cancer cells	Inhibited the cell proliferation, the phosphorylation of STAT3 at residue Y705, induces caspase-3-dependent apoptosis in ovarian cancer cells.	[25]
Hepatoprotective	Human lung adenocarcinoma cell lines (A549)	Arrested cancer cells proliferation at the G0/G1 phase, down-regulation of NPAT protein expression and E/CDK2 or cyclin H/CDK7, induced apoptosis while its cytotoxicity was enhanced by GSH synthase inhibitor.	[47]
	Toxoplasma gondii-induced liver damage in C57BL/6 mice	Enhanced cell viability and inhibited proliferation and iNOS, HMGB1 expression, TLR4/NF- κ B, ALT, AST levels in liver damaged mice.	[26]
	Concanavalin A (ConA)-induced acute hepatitis in male BALB/c mice	Inhibited congestion and necroinflammation of livers, ALT and AST, CD4T, NKT and macrophages, T-lymphocyte proliferations and stimulated IL-10 production	[28]
Effect on CNS	Oleic acid-induced lipid accumulation in WRL68 hepatocytes	Enhanced growth inhibition rate of WRL68 cells (IC ₅₀ 1730 μ M), inhibited the cell death rate, OA-induced lipid droplet accumulation and increased PPAR γ expression, cpt-1, phosphorylation levels of PI3K, Akt, and AMPK, decreased ACC1, SREBP-1, TBARS, ICAM-1, IL-1 β IL-6Sr, IL-7, IL-8, TNF α	[28]
	Toxoplasma gondii-infection induced depression in mice	ARG (100 mg/kg) attenuates microglial activation and neuro-inflammation by suppressing the TLR4/NF- κ B and TNFR1/NF- κ B signaling pathways in <i>T. gondii</i> infected mice	[34]
Renoprotective	Acute and chronic stress-induced depressive- and anxiety-like behaviors in male ICR mice by OFT, NSF, SPT, FST, TST test.	Inhibited immobility time, floating time FST, latency to feeding time in NSF, Enhanced the latency of immobility time in TST, sucrose preference in SPT peripheral ANG, TPO and VEGF levels in chronic stress	[33]
	Diabetic mouse kidney disease	Stimulated PP2A activity, glucoseinduced migration in cultured podocytes via interaction with Drebrin-1, podocyte-specific Pp2a deletion and ATG mediated renoprotection.	[29]
	Estrogen receptor stress-induced cell apoptosis in HK2 cells. Diabetes-related renal injury in db/db mice	ARG inhibited high glucose activated ER stress signal transduction pathway and induced cell apoptosis in HK2 cells ARG reduced blood glucose, urine albumin excretion, and urine albumin to creatinine ratio, and attenuated renal pathological injury as well as ER stress-related markers expression and caspase 12 level in db/db mice.	[30]
	Ischemia/reperfusion induced acute kidney injury in male C57BL/6 mice.	Inhibited cytokine, TLR4/MyD88, and NF- κ B, CD68+ macrophage, CD11b+Gr1+ neutrophil, MDA, iNOS, caspase-3& 9 expression and enhanced SOD, GPx, apoptosis, numbers of TUNEL positive cells, Bcl-2, Bax	[31]
Anti-fibrosis	Unilateral ureteral obstruction induced injury and fibrogenesis in male Sprague-Dawley rats	Inhibited tubular dilatation, epithelial atrophy, collagen deposition, and tubulointerstitial compartment expansion, MCP-1 and TNF- α , IL-1 β , IFN- γ , NF- κ B, lipid peroxidation, TGF- β 1, Smad2/3 phosphorylation and nuclear translocation. Enhanced SOD, Smad7 expression.	[32]
	Buccal mucosal fibroblasts (BMFs) and fibrotic BMFs (fBMFs)	ARG showed anti-fibrosis effect with IC ₅₀ 354.5 and 133 against BMFs and fBMFs as well as inhibited arecoline-induced collagen contraction and migration capacities of BMF, invasion and wound healing, collagen gel contraction and invasion capabilities, suppresses the myofibroblast in fBMFs and represses the expression of myofibroblast markers and the TGF- β /Smad2 signaling of fBMFs.	[48]
Osteoprotective	RANKL-induced differentiation of bone marrow-derived macrophages Titanium-induced osteolysis male C57BL/6J mice	ARG inhibited RANKL-induced osteoclastogenesis, osteoclastic marker genes expression, hydroxyapatite resorption, NF- κ B activation, I κ Ba p65 and nuclear translocation in bone marrow-derived macrophages. ARG inhibited titanium-induced osteolysis, bone destruction, osteoclasts in C57BL/6 male mice	[44]
Immunomodulatory	Porcine alveolar macrophage cell line (3D4/21) and primary porcine derived alveolar macrophage	ARG enhanced TNF- α , TGF- β 1, ROS by activating NOX2-based NADPH oxidase, phagocytosis, expression and secretions of TNF- α and TGF- β 1 in 3D4/21 cells. In primary porcine Arg inhibited macrophages and cytokine secretion.	[49]

Antioxidant	Nitrite scavenging activity	Inhibited nitrite free radicals with IC ₅₀ 17.49 mg/ml	[43]
	DPPH assay	ARG showed potent free radical scavenging activity with EC ₅₀ 0.0160 mg/ml as compared to BHT (EC ₅₀ 0.0162 mg/ml)	[50]
Anti-allergic	Mast cell-mediated allergic inflammation Compound 48/80-induced anaphylactic shock and Passive cutaneous anaphylaxis in ICR mice	ARG reduced the production of histamine and pro-inflammatory cytokines such as interleukin (IL)-20, IL-1β, IL-6, IL-8, TNF-α as well as phosphorylation of 21 MAPKs and NF-κB in mast cells. Arg suppressed IgE-mediated passive cutaneous anaphylaxis and compound 48/80-induced anaphylactic shock in diseased ICR mice.	[51]
Neuroprotective	Cerebral ischemia injury in Sprague-Dawley rats	Enhanced brain infarct volume, NLRP3, ASC, caspase-1 p20, IL-1β and IL-18 proteins expression, SIRT1 protein Inhibited the neurological score	[35]
	Alzheimer's Disease Mice Model	Inhibit Aβ production through β-site amyloid precursor protein cleavage enzyme 1 expression suppression and stimulates Aβ clearance by inhibiting AKT/mTOR signaling and activation of AMPK/Raptor pathway in diseased mice.	[52]
	Ethanol-induced cell damage in PC12 cells.	Enhanced cell viability, number of cells in the G2/M phase, inhibited apoptosis and necrosis	[36]
	Y-maze and Morris water maze tests in scopolamine-induced memory deficit ICR mice	Reduced memory deficit in mice by 62% at 60 mg/kg and significantly reversed the memory deficits in the Y-maze and Morris water maze tests.	[37]
	Sprague-dawley rats with brain ischemia injury	Inhibited cerebral infarction and improved neurological outcome, activation of microglia, interleukin (IL)-1β, tumor necrosis factor (TNF)-α.	[38]
Gastroprotective	Ethanol and acetic acid induced ulcer in Sprague-Dawley rat	Inhibited gastric lesion TNF-α, IL-6, IL-10, C-reactive protein, MDA and stimulated SOD in rat serum	[42]
Anti-colitis	Dextran sulfate sodium (DSS)-induced colitis in male C57BL/6 mice.	ARG inhibits differentiation of Th17, phosphorylation of STAT3 and STAT4, p70S6K and RPS6, mTORC1 and stimulated cytokine levels (IFN-γ and IL-17A), mRNA expressions of transcription factor (T-bet and RORγt) as well as cell counts of Th1 and Th17 (IFN-γ+CD4+, IFN-γ+IL-17A+CD4+ and IL-17A+CD4+ T cell)	[53]
	Dextran sulfate sodium-induced colitis in male C57BL/6 mice.	Recovered the loss of intestinal epithelial cells and inhibited the infiltration of neutrophils, TNF-α, IL-6, MIP-6, MCP-1, MadCAM-1, ICAM-1 & VCAM-1, also reduced MDA, increased SOD & GSH level.	[28]
Anti-diabetic	Hypoglycemic Goto-Kakizaki (GK) rats	Inhibited plasma glucose, glycosylated hemoglobin and improve glucose tolerance	[54]
Anti-hypertensive	Hypertensive rats (SHR)	Inhibited systolic blood pressure, thromboxane b2 in plasma, superoxide anion in thoracic, expression of NADPH oxidase in thoracic aorta, enhanced the NO production by phosphorylation of akt and Enos.	[39]
Vasorelaxant	Airway smooth muscle (ASM) cells	Inhibited Ca ²⁺ influx partly through L-type calcium channel as well as enhancing Ca ²⁺ efflux.	[40]
Cytoprotective	ER stress-induced BFA-induced apoptosis in HepG2 cells and palmitate-induced cell death in INS-1 β-cells	Inhibited cell death and unfolded protein response (UPR), protein synthesis, intracellular ATP level, AMPK and activated AMPK, decreased ER stress, cell death induced by palmitate	[41]
Enzyme inhibitory	α-MSH-mediated melanogenesis in B16BL6 Cells	Inhibited tyrosinase activity and melanin content in α-melanocyte stimulating hormone-stimulated cells. It dose dependently decreased the cAMP level and promoted the phosphorylation of extracellular signal-regulated kinase.	[55]
	Acetylcholinesterase (AChE)	Inhibited AChE with IC ₅₀ 0.462 mg/ml	[50]

CONCLUSION AND FUTURE PROSPECTIVE

The *Articum lappa* L., a member of the biggest flowering plant family, the Asteraceae, is commonly known as burdock and plays a significant role in traditional Chinese (Niupang), Japanese (Gobo), and other Asian medicinal systems. There are various studies in the literature that show the vast range of possible pharmacological uses of Arctigenin as one of the major active natural compounds found in burdock seeds. Among the 18 various pharmacological activities of ARG, anti-inflammatory and anticancer activities were reported to be very high, which is encouraging for the therapeutic application of ARG in the treatment of chronic disorders like cancer, diabetes, and inflammation. According to our review, the compound is beneficial in treating inflammatory and skin disorders as well as cancers of the stomach, lungs, liver, and colon. It also provides information on the potential advantages and disadvantages of using burdock seeds as a functional food. We come to the conclusion that additional research is necessary to gain a clearer mechanistic understanding of the reported and unique functions in the prevention and treatment of human diseases, as well as any potential adverse effects.

Acknowledgements

The authors are thankful to the revered Swami Ramdev for his continuous motivational support for the research work. The authors are also thankful to Patanjali Research Institute, Haridwar for financial assistance.

Conflict of Interest

The authors declare that they have no conflict of interest.

ORCID ID

Acharya Balkrishna: <https://orcid.org/0000-0003-3215-3127>

Vidhi Dobhal: <https://orcid.org/0000-0001-9615-1345>

Sonam Verma: <https://orcid.org/0000-0002-6323-9284>

Deepika Srivastava: <https://orcid.org/0000-0001-5234-4364>

Shalini Singh: <https://orcid.org/0000-0002-3743-8888>

Vedpriya Arya: <https://orcid.org/0000-0001-7562-1731>

REFERENCES

- Susanti S, Iwasaki H, Itokazu Y, Nago M, Taira N, Saitoh S, *et al.* Tumor specific cytotoxicity of arctigenin isolated from herbal plant *Arctium lappa* L. The Japanese Society of Pharmacognosy and Springer. 2012;66(4):614-21.
- Vasisht K, Sharma N, Karan. Current Perspective in the International Trade of Medicinal Plants Material: An Update ADD TO CART BUY NOW [Internet]. Current Pharmaceutical Design. 2016;27(49):4288-4336.
- Hu J, Shi Y, Yang B, Dong Z, Si X, Qin K. Changes in chemical components and antitumor activity during the heating process of Fructus Arctii. Pharmaceutical Biology. 2019;57(1):363-8.
- Anvari D, Jamei R. Evaluation of Antioxidant Capacity and Phenolic Content in Ethanolic Extracts of Leaves and Flowers of Some Asteraceae Species. Recent Patents on Food, Nutrition & Agriculture. 2018;9:42-49.
- Wang D, Bădăraș AS, Swamy MK, Shaw S, Maggi F, da Silva LE, *et al.* Arctium species secondary metabolites chemodiversity

- and bioactivities. Vol. 10, *Frontiers in Plant Science*. 2019;10:1-27.
6. Liu J, Cai YZ, Wong RNS, Lee CKF, Tang SCW, Sze SCW, *et al.* Comparative analysis of caffeoylquinic acids and lignans in roots and seeds among various burdock (*Arctium lappa*) genotypes with high antioxidant activity. *Journal of Agricultural and Food Chemistry*. 2012;60(16):4067-75.
7. Gurunanselage Don RAS, Yap MKK. *Arctium lappa* L. root extract induces cell death via mitochondrial-mediated caspase-dependent apoptosis in Jurkat human leukemic T cells. *Biomedicine & Pharmacotherapy*. 2019;110:918-929.
8. De Oliveira JR, De Aguiar Almeida RB, Das Graças Figueiredo Vilela P, De Oliveira FE, Da Rocha RF, Jorge AOC, *et al.* Control of microorganisms of oral health interest with *Arctium lappa* L. (burdock) extract non-cytotoxic to cell culture of macrophages (RAW 264.7). *Archives Oral Biology*. 2014;59(8):808-14.
9. Lee J, Ha SJ, Park J, Kim YH, Lee NH, Kim YE, *et al.* *Arctium lappa* root extract containing L-arginine prevents TNF- α -induced early atherosclerosis in vitro and in vivo. *Nutrition Research*. 2020;1(77):85-96.
10. Ahangarpour A, Heidari H, Akbar Oroojan A, Mirzavandi F, Nasr Esfehiani K, Dehghan Mohammadi Z, *et al.* Antidiabetic, hypolipidemic and hepatoprotective effects of *Arctium lappa* root's hydro-alcoholic extract on nicotinamide-streptozotocin induced type 2 model of diabetes in male mice. *Avicenna Journal of Phytomedicine*. 2017;7(2):169-179.
11. Zhao J, Chen Y, Dong L, Li X, Dong R, Zhou D, *et al.* Arctigenin protects mice from thioglycollate-induced acute peritonitis. *Pharmacol Res Perspect*. 2020;1-11.
12. Shi H, Zhao L, Guo X, Fang R, Zhang H, Dong G, *et al.* Arctigenin attenuates breast cancer progression through decreasing GM-CSF/TSLP/STAT3/ β -catenin signaling. *International Journal of Molecular Sciences*. 2020;21:1-18.
13. Jiang Y, Liu J, Hong W, Fei X, Liu R. Arctigenin Inhibits Glioblastoma Proliferation through the AKT/mTOR Pathway and Induces Autophagy. *BioMed Research International*. 2020;1-13.
14. Chan YS, Cheng LN, Wu JH, Chan E, Kwan YW, Lee SMY, *et al.* A review of the pharmacological effects of *Arctium lappa* (burdock). *Inflammopharmacology*. 2011;19(5):245-54.
15. Shi H, Dong G, Yan F, Zhang H, Li C, Ma Q, *et al.* Arctigenin Ameliorates Inflammation by Regulating Accumulation and Functional Activity of MDSCs in Endotoxin Shock. *Inflammation*. 2018;41(6):2090-100.
16. Zhang W zhou, Jiang Z kui, He B xia, Liu X ben. Arctigenin Protects against Lipopolysaccharide-Induced Pulmonary Oxidative Stress and Inflammation in a Mouse Model via Suppression of MAPK, HO-1, and iNOS Signaling. *Inflammation*. 2015;38(4):1406-14.
17. Hyam SR, Lee IA, Gu W, Kim KA, Jeong JJ, Jang SE, *et al.* Arctigenin ameliorates inflammation in vitro and in vivo by inhibiting the PI3K/AKT pathway and polarizing M1 macrophages to M2-like macrophages. *European Journal of Pharmacology*. 2013;708(1-3):21-9.
18. Lu Z, Chang L, Zhou H, Liu X, Li Y, Mi T, *et al.* Title: Arctigenin attenuates tumor metastasis through inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma via suppressing GSK3 β -dependent Wnt/ β -catenin signaling pathway in vivo and in vitro. *Frontier in Pharmacology*. 2019;10:1-12.
19. Ke N, Liu Q, Pi L, Fang J, Chen L, Chen X. The antitumor function of arctigenin in human retinoblastoma cells is mediated by jagged-1. *Molecular Medicine Report*. 2019;49(5):3642-8.
20. Sun Y, Tan Y jun, Lu ZZ, Li BB, Sun CH, Li T, *et al.* Arctigenin inhibits liver cancer tumorigenesis by inhibiting gankyrin expression via C/EBP α and PPAR α . *Frontier in Pharmacology*. 2018;1-12.
21. Wang P, Solorzano W, Diaz T, Magyar CE, Henning SM, Vadgama JV. Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. *Clinical Nutrition Experimental*. 2017;13:1-11.
22. Feng T, Cao W, Shen W, Zhang L, Gu X, Guo Y, *et al.* Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. *Oncotarget*. 2017;8(1):329-344.
23. Maxwell T, Chun SY, Lee KS, Kim S, Nam KS. The anti-metastatic effects of the phytoestrogen arctigenin on human breast cancer cell lines regardless of the status of ER expression. *International Journal of Oncology*. 2017;50(2):727-35.
24. Su S, Cheng X, Wink M. Natural lignans from *Arctium lappa* modulate P-glycoprotein efflux function in multidrug resistant cancer cells. *Phytomedicine*. 2015;22(2):301-7.
25. Huang K, Li LA, Meng YG, You YQ, Fu XY, Song L. Arctigenin Promotes Apoptosis in Ovarian Cancer Cells via the iNOS/NO/STAT3/Survivin Signalling. *Basic & Clinical Pharmacology and Toxicology*. 2014;115(6):507-11.
26. Lu YN, Zhao XD, Xu X, Piao J, Aosai F, Li YB, *et al.* Arctigenin exhibits hepatoprotective activity in Toxoplasma gondii-infected host through HMGB1/TLR4/NF- κ B pathway. *International Immunopharmacology*. 2020;1:84.
27. Cheng X, Wang H, Yang J, Cheng Y, Wang D, Yang F, *et al.* Arctigenin protects against liver injury from acute hepatitis by suppressing immune cells in mice. *Biomed Pharmacother*. 2018;102:464-71.
28. Wu X, Yang Y, Dou Y, Ye J, Bian D, Wei Z, *et al.* Arctigenin but not arctiin acts as the major effective constituent of *Arctium lappa* L. fruit for attenuating colonic inflammatory response induced by dextran sulfate sodium in mice. *International Immunopharmacology*. 2014;23(2):505-15.
29. Zhong Y, Lee K, Deng Y, Ma Y, Chen Y, Li X, *et al.* Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes. *Nature Communications*. 2019;1-13.
30. Zhang J, Cao P, Gui J, Wang X, Han J, Wang Y, *et al.* Arctigenin ameliorates renal impairment and inhibits endoplasmic reticulum stress in diabetic db/db mice. *Life Sciences*. 2019;223:194-201.
31. Han F, Xia X xin, dou M, Wang Y xiang, Xue WJ, Ding XM, *et al.* Arctigenin: A two-edged sword in ischemia/reperfusion induced acute kidney injury. *Biomedicine & Pharmacotherapy*. 2018;103:1127-36.
32. Li A, Zhang X, Shu M, Wu M, Wang J, Zhang J, *et al.* Arctigenin suppresses renal interstitial fibrosis in a rat model of obstructive nephropathy. *Phytomedicine*. 2017;30:28-41.
33. Du Y, Li W, Li Y, Yang J, Wang X, Yin S, *et al.* Repeated arctigenin treatment produces antidepressant- and anxiolytic-like effects in mice. *Brain Research Bulletin*. 2019;146:79-86.
34. Cheng JH, Xu X, Li YB, Zhao XD, Aosai F, Shi SY, *et al.* Arctigenin ameliorates depression-like behaviors in Toxoplasma gondii-infected intermediate hosts via the TLR4/NF- κ B and TNFR1/NF- κ B signaling pathways. *International Immunopharmacology*. 2020;1-14.
35. Zhang S, Jiang L, Che F, Lu Y, Xie Z, Wang H. Arctigenin attenuates ischemic stroke via SIRT1-dependent inhibition of NLRP3 inflammasome. *Biochemical and Biophysical Research Communications*. 2017;493(1):821-6.
36. Huang J, Xiao L, Wei JX, Shu YH, Fang SQ, Wang YT, *et al.* Protective effect of arctigenin on ethanol-induced neurotoxicity in PC12 cells. *Molecular Medicine Reports*. 2017;15(4):2235-40.
37. Lee IA, Joh EH, Kim DH. Arctigenin isolated from the seeds of *Arctium lappa* ameliorates memory deficits in mice. *Planta Medica*. 2011;77(13):1525-7.
38. Fan T, Jiang WL, Zhu J, Zhang YF. Arctigenin Protects Focal Cerebral Ischemia-Reperfusion Rats through inhibiting Neuroinflammation. 2004;35(11)2004-2009.
39. Liu Y, Wang G, Yang M, Chen H, Zhao Y, Yang S, *et al.* Arctigenin reduces blood pressure by modulation of nitric oxide synthase and NADPH oxidase expression in spontaneously hypertensive rats. *Biochemical and Biophysical Research Communications*. 2015;468(4):837-42.

40. Zhao Z, Yin Y, Wang Z, Fang R, Wu H, Jiang M, *et al.* Arctigenin exhibits relaxation effect on bronchus by affecting transmembrane flow of calcium. *Biological Trace Element Research*. 2013;156(1-3):181-7.
41. Gu Y, Sun XX, Ye JM, He L, Yan SS, Zhang HH, *et al.* Arctigenin alleviates ER stress *via* activating AMPK. *Acta Pharmaceutica Sinica B*. 2012;33(7):941-52.
42. Li XM, Miao Y, Su QY, Yao JC, Li HH, Zhang GM. Gastroprotective effects of arctigenin of *Arctium lappa* L. On a rat model of gastric ulcers. *Biomedical Reports*. 2016;5(5):589-94.
43. Cai E, Han J, Yang L, Zhang W, Zhao Y, Chen Q, *et al.* Novel Method of Preparation and Activity Research on Arctigenin from Fructus Arctii. *Pharmacognosy Magazine*. 2018;14(53):87-94.
44. Wei G, Liang T, Wei C, Nong X, Lu Q, Zhao J. Arctigenin inhibits RANKL-induced osteoclastogenesis and hydroxyapatite resorption *in vitro* and prevents titanium particle-induced bone loss *in vivo*. *Journal of Cellular Biochemistry*. 2019;120(4):5367-76.
45. Lee KS, Lee MG, Kwon YS, Nam KS. Arctigenin enhances the cytotoxic effect of doxorubicin in MDA-MB-231 breast cancer cells. *International Journal of Molecular Sciences*. 2020;21:1-18.
46. Lou C, Zhu Z, Zhao Y, Zhu R, Zhao H. Arctigenin, a lignan from *Arctium lappa* L., inhibits metastasis of human breast cancer cells through the downregulation of MMP-2/-9 and heparanase in MDA-MB-231 cells. *Oncology Reports*. 2017;37(1):179-84.
47. Susanti S, Iwasaki H, Inafuku M, Taira N, Oku H. Mechanism of arctigenin-mediated specific cytotoxicity against human lung adenocarcinoma cell lines. *Phytomedicine*. 2013;21(1):39-46.
48. Lin CY, Hsieh PL, Liao YW, Peng CY, Yu CC, Lu MY. Arctigenin reduces myofibroblast activities in oral submucous fibrosis by LINC00974 inhibition. *International Journal of Molecular Sciences*. 2019;20:1-11.
49. Lu Z, Chang L, Du Q, Huang Y, Zhang X, Wu X, *et al.* Arctigenin induces an activation response in porcine alveolar macrophage through TLR6-NOX2-MAPKs signaling pathway. *Frontiers in Pharmacology*. 2018;9:1-15.
50. Lü H, Sun Z, Shan H, Song J. Microwave-assisted extraction and purification of arctiin and arctigenin from fructus arctii by high-speed countercurrent chromatography. *Journal of Chromatographic Science*. 2016;54(3):472-8.
51. Kee JY, Hong SH. Inhibition of Mast Cell-Mediated Allergic Responses by Arctii Fructus Extracts and Its Main Compound Arctigenin. *Journal of Agricultural and Food Chemistry*. 2017;65(43):9443-52.
52. Zhu Z, Yan J, Jiang W, Yao XG, Chen J, Chen L, *et al.* Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both β -amyloid production and clearance. *Journal of Neuroscience*. 2013;33(32):13138-49.
53. Wu X, Dou Y, Yang Y, Bian D, Luo J, Tong B, *et al.* Arctigenin exerts anti-colitis efficacy through inhibiting the differentiation of Th1 and Th17 cells *via* an mTORC1-dependent pathway. *Biochemical Pharmacology*. 2015;96(4):323-36.
54. Xu Z, Gu C, Wang K, Ju J, Wang H, Ruan K, *et al.* Arctigenic acid, the key substance responsible for the hypoglycemic activity of Fructus Arctii. *Phytomedicine*. 2015;22(1):128-37.
55. Park H, Song KH, Jung PM, Kim JE, Ro H, Kim MY, *et al.* Inhibitory effect of arctigenin from Fructus arctii extract on melanin synthesis *via* repression of tyrosinase expression. *Evidence-Based Complementary and Alternative Medicine*. 2013;1-10.

HOW TO CITE THIS ARTICLE

Balkrishna A, Dobhal V, Verma S, Srivastava D, Singh S, Arya V. Arctigenin: A Potential Component with Multifaceted Therapeutic Properties. *J Phytopharmacol* 2022; 11(6):414-420. doi: 10.31254/phyto.2022.11607

Creative Commons (CC) License-

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY 4.0) license. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (<http://creativecommons.org/licenses/by/4.0/>).